Targeted Medical Pharma Inc · OTC:TRGM
Targeted Medical Pharma — Investor Presentation (January 2013)
31 slides from Targeted Medical Pharma's investor presentation, Jan 7, 2013
Slide 1: Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology
Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology January 2013
Slide 2: Safe Harbor Statement
Safe Harbor Statement This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities . Targeted Medical Pharma, Inc . (“Targeted Medical Pharma”, “TMP” or “the Company”) shall not have any responsibility for any such violations . This do
Slide 3: Biotechnology Company with Established Distribution Channels
Biotechnology Company with Established Distribution Channels TARGETED MEDICAL PHARMA 3
Slide 4: Company Snapshot
Company Snapshot TARGETED MEDICAL PHARMA Biotechnology company founded in 1999, publicly traded as of October 2012 on OTCBB : TRGM Low - cost development platform A technology that is applicable to multiple diseases Replaces pharmaceuticals that have harmful side effects Ten core proprietary Rx - On
Slide 5: About Rx-Only Medical Foods
Must make a disease claim Require physician prescription and supervision Regulated as drugs prior to 1972 Enteral administration GRAS ingredients Address specific nutritional deficiencies Do not require FDA pre - approval Medical foods are FDA - regulated medications intended for the dietary managem
Slide 6: Targeted Cellular Technology
Five - component System Stimulates Uptake and Utilization of Amino Acids Targeted Cellular Technology TARGETED MEDICAL PHARMA 6
Slide 7: Product Rollout and Pipeline
Drug Indication In Development Clinical Trials On Market and Reimbursed Medical Food Co-Packs Multiple disease states x Theramine 90 Fibromyalgia x Sentra PM Sleep Disorders with Depression x Sentra AM Cognitive Disorders / Fatigue x Trepadone 90 Osteoarthritis x GABAdone Sleep Disorders with Anxiet
Slide 8: Clinical Studies Programs
• Obesity and Metabolic Syndrome with Apptrim® (2001) • Hypertension with Hypertensa® (2003) • Sleep disorders with Sentra PM® and GABAdone® (2003) • Cognitive dysfunction with Sentra AM® (2003) • Osteoarthritis with Trepadone® and Theramine® (2003) • Fibromyalgia with Theramine®, Sentra PM® and Sen
Slide 9: Medical Foods: Meeting Physician & Patient Demand
Improve Patient Outcomes Reduce Negative Side Effects Lower Costs Nutritional Management of Chronic Disease Generally Recognized as Safe Clinical Trials Prove Efficacy Reduce Dosage of Opiates Improved Adherence SOLUTIONS NEEDS Medical Foods: Meeting Physician & Patient Demand TARGETED MEDICAL PHARM
Slide 10: The Basis for Low-Cost Research and Development
The Basis for Low - Cost Research and Development Exemption No safety trials, only efficacy must be demonstrated Registration 60 products registered with the FDA Categorization 2 Categorized as an old drug Regulation 1 Regulated under the FDA’s medical food definition 1 Regulation • Must be administ
Slide 11: Clinical Trial: Theramine with Naproxen
Primary Uses Reduction of Pain and Inflammation Clinical Trial: Theramine® with Naproxen (Theraproxen®) TARGETED MEDICAL PHARMA 11
Slide 12: Reduction in C-Reactive Protein with Theramine
Countering NSAID’s inflammatory marker effects Reduction in C - Reactive Protein with Theramine® TARGETED MEDICAL PHARMA 12
Slide 13: Clinical Trial: Theramine with Ibuprofen
Treatment of Low Back Pain Primary Uses Clinical Trial: Theramine® with Ibuprofen (Theraprofen®) TARGETED MEDICAL PHARMA 13
Slide 14: Clinical Trial: Sentra PM and Trazodone
Clinical Trial: Sentra PM® and Trazodone ( Trazamine ®) Management of Sleep Disorders 0.95 1.98 3.86 6.48 0 2 4 6 8 10 - Point Scale Sleep Quality (PSEQ) Change from baseline at Day 14 Placebo Trazodone Sentra PM Both Primary Uses TARGETED MEDICAL PHARMA 14
Slide 15: Initial Data: ESS-1818
- 20,000 40,000 60,000 80,000 100,000 120,000 1 2 5 7 17 Effect of ESS on Reticulocyte Count 1 Reticulocytes Stimulation of Red Blood Cell Precursors 1 Effect on one patient in pre - clinical trials. Pre - clinical trials resulted in an 80% response rate. Treatment Initiated Treatment Discontinued P
Slide 16: Pharmacoeconomic Analysis of Theramine
Pharmacoeconomic Analysis of Theramine TARGETED MEDICAL PHARMA Theramine NSAID Product 633,600,000$ 36,000,000$ GI Bleed Treatment - 225,000,000 Protective Medications - 432,000,000 Laboratory Testing 1,000,000 75,000,000 Negative GI Workup - 144,000,000 Total 634,600,000$ 912,000,000$ Comparative A
Slide 17: Intellectual Property Highlights
Intellectual Property Highlights TARGETED MEDICAL PHARMA 特許 Six Issued Patents Four Patents Pending □ 4 USPTO neurotransmitter - specific patents covering Targeted Cellular Technology® (TCT) □ 1 USPTO patent covering the convenience pack presentation □ 1 Japanese patent covering TMP’s Targeted Cellu
Slide 18: Financials and Team
Innovators in Pharmaceutical Technology Financials and Team
Slide 19: Financial Snapshot – Fiscal Year 2011
Financial Snapshot – Fiscal Year 2011 Summary December 31, 2011 Revenue $8.8 million Operating Expenses $11.8 million Shares Outstanding 22.0 million Shares: Fully Diluted 28.6 million Other Information Comments Non - Recurring Expense $1.5mm in non recurring expense (includes $950,000 related to go
Slide 20: Contract Receivables
Shipments : Contract Receivables Collections : Recognized Revenue Prior revenue recognition practices led to “Contract Receivables” Monthly collections are approximately 1.5% to 2.0% Collected amounts impact bottom - line operating revenue almost directly Contract receivables are constantly rejuvena
Slide 21: Improving the Reimbursement Mix
Improving the Reimbursement Mix TARGETED MEDICAL PHARMA 21 0% 10% 20% 30% 40% 50% 60% 70% 80% 2011 2012 2013 2014 Workers Comp Private Insurance Medicare Part D DOD / VA
Slide 22: Financial, Collection and Sales Data
Financial, Collection and Sales Data TARGETED MEDICAL PHARMA $400,000 $500,000 $600,000 $700,000 $800,000 $900,000 $1,000,000 Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Monthly Collections Growth Trend Quarterly Invoice Trend $3,400,000 $3,500,000 $3,600,000 $3,700,000 $3,800,000 $3,900,000 $4,000,00
Slide 23: Reimbursement Channels
Reimbursement Channels TARGETED MEDICAL PHARMA 2 3 Medicare Part D DOD / VA Medicaid Tricare Cigna BlueCross/Blue Shield United Healthcare Aetna Health Net Rx Solutions Medco Caremark Catamaran (Walgreens) MedImpact Express Scripts Workers ’ Compensation Private Insurance Medicare Secondary Insuranc
Slide 24: Cambridge Medical Funding Group
Cambridge Medical Funding Group TARGETED MEDICAL PHARMA 24 Turning Long Term Receivables into Cash and Short Term Receivables • Contract signed on November 20, 2012, now performing • Workers compensation revolving assignment of new A/R • Paid within 5 days of dispense, not dependent on collection da
Slide 25: Federal Supply Schedule (FSS)
Federal Supply Schedule (FSS) TARGETED MEDICAL PHARMA 25 Five core products approved for FSS Allows federal agencies to purchase product • Department of Defense • Veterans ’ Administration • Coast Guard • Department of Health and Human Services • State Department • Homeland Security Contracted with
Slide 26: Medicare and Private Insurance
Medicare and Private Insurance TARGETED MEDICAL PHARMA 26 Current status • Medicare Advantage • Medicare Supplemental • > 50% of Formulary exemption challenges • Increasing Judicial acceptance of dual status of Medical Food and old drug, thus a covered drug • PPO and PBM Payers Future Direction • Co
Slide 27: Profitability Drivers
Profitability Drivers TARGETED MEDICAL PHARMA National Sales Growth Increased Formulary Acceptance Overseas Sales Growth Institutional & Military Sales Increased Collections Rate Launch Pipelined Products 27
Slide 28: Management Team
William Shell, M.D. Co - Founder, CEO and Chief Science Officer Extensive background in science and medicine, including roles as director of the Keesler Air Force Base Coronary Care Unit and director of the Cardiovascular Biochemistry Research Laboratories at Cedars Sinai Medical Center. Served as c
Slide 29: Board of Directors
Independent: Maurice J. DeWald - Chairman of the Board and Compensation Committee • Retired board member and regional managing partner at KPMG • Serves as board director for several healthcare companies Kerry Weems - Chair of Nominating and Corporate Governance Committees • Former administrator for
Slide 30: Investment Considerations
Investment Considerations HIGH DEMAND PRODUCTS ADDRESSING LARGE MARKETS 1 GROWING ADOPTION OF MEDICAL FOODS 2 ROBUST PIPELINE 3 STRONG AND VALUABLE INTELLECTUAL PROPERTY PORTFOLIO 4 PROVEN SAFETY AND EFFICACY THROUGH CLINICAL TRIALS 5 LOW SIDE - EFFECT PROFILE 6 LOW - COST DEVELOPMENT PLATFORM / FAS
Slide 31: Contact
Contact 2980 Beverly Glen Circle, Suite 301 Los Angeles, CA 90077 Telephone: 310 - 474 - 9809 Fax: 310 - 531 - 7089 investors@tmedpharma.com Brand site: www.ptlcentral.com Company site: www.tmedpharma.com
Targeted Medical Pharma — Investor Presentation (January 2013) on 6ix